NO317938B1 - Pantropisk neurotrofinpolypeptid, fremgangsmate for fremstilling av dette, isolert nukleinsyre, ekspresjonsvektor, vertscelle samt farmasoytisk preparat - Google Patents
Pantropisk neurotrofinpolypeptid, fremgangsmate for fremstilling av dette, isolert nukleinsyre, ekspresjonsvektor, vertscelle samt farmasoytisk preparat Download PDFInfo
- Publication number
- NO317938B1 NO317938B1 NO19965123A NO965123A NO317938B1 NO 317938 B1 NO317938 B1 NO 317938B1 NO 19965123 A NO19965123 A NO 19965123A NO 965123 A NO965123 A NO 965123A NO 317938 B1 NO317938 B1 NO 317938B1
- Authority
- NO
- Norway
- Prior art keywords
- hngf
- amino acid
- trka
- binding
- ngf
- Prior art date
Links
- 108010025020 Nerve Growth Factor Proteins 0.000 title claims abstract description 297
- 102000007072 Nerve Growth Factors Human genes 0.000 title claims abstract description 194
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 32
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 31
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 31
- 239000013604 expression vector Substances 0.000 title claims abstract description 26
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 5
- 238000000034 method Methods 0.000 title description 42
- 238000002360 preparation method Methods 0.000 title description 5
- 230000008569 process Effects 0.000 title description 2
- 101001111439 Homo sapiens Beta-nerve growth factor Proteins 0.000 claims description 210
- 102000046917 human NGF Human genes 0.000 claims description 209
- 230000027455 binding Effects 0.000 claims description 153
- 101100222854 Bacillus subtilis (strain 168) czcO gene Proteins 0.000 claims description 139
- 101100537961 Methanosarcina mazei (strain ATCC BAA-159 / DSM 3647 / Goe1 / Go1 / JCM 11833 / OCM 88) trkA2 gene Proteins 0.000 claims description 139
- 101150025395 trkA gene Proteins 0.000 claims description 139
- 101150113435 trkA1 gene Proteins 0.000 claims description 139
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 103
- 102000047459 trkC Receptor Human genes 0.000 claims description 68
- 108010064892 trkC Receptor Proteins 0.000 claims description 68
- 235000001014 amino acid Nutrition 0.000 claims description 61
- 150000001413 amino acids Chemical class 0.000 claims description 46
- 101100127166 Escherichia coli (strain K12) kefB gene Proteins 0.000 claims description 33
- 238000006467 substitution reaction Methods 0.000 claims description 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 101000634196 Homo sapiens Neurotrophin-3 Proteins 0.000 claims description 25
- 102000057714 human NTF3 Human genes 0.000 claims description 25
- 230000014509 gene expression Effects 0.000 claims description 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- 229920001184 polypeptide Polymers 0.000 claims description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 22
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 claims description 20
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 claims description 19
- 102220576986 C5a anaphylatoxin chemotactic receptor 1_D15A_mutation Human genes 0.000 claims description 11
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 102220500296 M-phase phosphoprotein 6_T81K_mutation Human genes 0.000 claims description 7
- 102220563953 Vitamin K-dependent protein S_V18E_mutation Human genes 0.000 claims description 5
- 102200056309 rs74315288 Human genes 0.000 claims description 5
- 102200081227 rs755458782 Human genes 0.000 claims description 5
- 239000000833 heterodimer Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 102200097286 rs199472825 Human genes 0.000 claims description 3
- 239000000710 homodimer Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 102220509999 Putative POM121-like protein 1_K88R_mutation Human genes 0.000 claims 1
- 102220111532 rs572322476 Human genes 0.000 claims 1
- 239000003900 neurotrophic factor Substances 0.000 abstract description 12
- 230000001537 neural effect Effects 0.000 abstract description 10
- 230000000508 neurotrophic effect Effects 0.000 abstract description 10
- 210000004027 cell Anatomy 0.000 description 169
- 125000000539 amino acid group Chemical group 0.000 description 115
- 108090000742 Neurotrophin 3 Proteins 0.000 description 111
- 102100029268 Neurotrophin-3 Human genes 0.000 description 111
- 229940053128 nerve growth factor Drugs 0.000 description 101
- 229940032018 neurotrophin 3 Drugs 0.000 description 78
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 59
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 59
- 108020003175 receptors Proteins 0.000 description 56
- 102000005962 receptors Human genes 0.000 description 55
- 230000000694 effects Effects 0.000 description 41
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 39
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 39
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 39
- 230000035578 autophosphorylation Effects 0.000 description 36
- 230000035772 mutation Effects 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 28
- 210000002569 neuron Anatomy 0.000 description 27
- 238000004458 analytical method Methods 0.000 description 25
- 235000018102 proteins Nutrition 0.000 description 25
- 101100404651 Mus musculus Ngf gene Proteins 0.000 description 24
- 102000004169 proteins and genes Human genes 0.000 description 24
- 238000006073 displacement reaction Methods 0.000 description 23
- 230000003993 interaction Effects 0.000 description 23
- 239000000178 monomer Substances 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 21
- 230000014511 neuron projection development Effects 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 16
- 238000005259 measurement Methods 0.000 description 14
- 239000002609 medium Substances 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 13
- 239000003636 conditioned culture medium Substances 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 235000004279 alanine Nutrition 0.000 description 12
- 239000003446 ligand Substances 0.000 description 12
- 210000003594 spinal ganglia Anatomy 0.000 description 12
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 238000002703 mutagenesis Methods 0.000 description 10
- 231100000350 mutagenesis Toxicity 0.000 description 10
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000024245 cell differentiation Effects 0.000 description 9
- 238000003119 immunoblot Methods 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 238000001890 transfection Methods 0.000 description 9
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 210000002241 neurite Anatomy 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 241000276498 Pollachius virens Species 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 230000002860 competitive effect Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 210000004962 mammalian cell Anatomy 0.000 description 7
- 238000000159 protein binding assay Methods 0.000 description 7
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 235000021186 dishes Nutrition 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 238000011002 quantification Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 108090000099 Neurotrophin-4 Proteins 0.000 description 5
- 235000003704 aspartic acid Nutrition 0.000 description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 230000002209 hydrophobic effect Effects 0.000 description 5
- 238000003522 neurite outgrowth assay Methods 0.000 description 5
- 210000001044 sensory neuron Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 102000015533 trkA Receptor Human genes 0.000 description 5
- 108010064884 trkA Receptor Proteins 0.000 description 5
- 102220615571 40S ribosomal protein S13_K88R_mutation Human genes 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 101150069554 HIS4 gene Proteins 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 102000002067 Protein Subunits Human genes 0.000 description 4
- 108010001267 Protein Subunits Proteins 0.000 description 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 235000018417 cysteine Nutrition 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000009650 gentamicin protection assay Methods 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000001114 immunoprecipitation Methods 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 102220237855 rs1028530418 Human genes 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 241000701447 unidentified baculovirus Species 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 102220483699 Aminopeptidase RNPEPL1_R68A_mutation Human genes 0.000 description 3
- 102220614783 Calmodulin-3_R9A_mutation Human genes 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102100033857 Neurotrophin-4 Human genes 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000000211 autoradiogram Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000012148 binding buffer Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 235000013330 chicken meat Nutrition 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000009137 competitive binding Effects 0.000 description 3
- 239000013632 covalent dimer Substances 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 210000000609 ganglia Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000004897 n-terminal region Anatomy 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 210000001428 peripheral nervous system Anatomy 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 230000002889 sympathetic effect Effects 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 102000015534 trkB Receptor Human genes 0.000 description 3
- 108010064880 trkB Receptor Proteins 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102100026357 40S ribosomal protein S13 Human genes 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000003098 Ganglion Cysts Diseases 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 102000008300 Mutant Proteins Human genes 0.000 description 2
- 108010021466 Mutant Proteins Proteins 0.000 description 2
- 101150111783 NTRK1 gene Proteins 0.000 description 2
- 102000003683 Neurotrophin-4 Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000005400 Synovial Cyst Diseases 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- -1 aspartyl Chemical group 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000006727 cell loss Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000002932 cholinergic neuron Anatomy 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000005661 hydrophobic surface Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000001466 metabolic labeling Methods 0.000 description 2
- 238000000302 molecular modelling Methods 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- 229940097998 neurotrophin 4 Drugs 0.000 description 2
- 230000002474 noradrenergic effect Effects 0.000 description 2
- 208000027232 peripheral nervous system disease Diseases 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000004129 prosencephalon Anatomy 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000008054 signal transmission Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000000331 sympathetic ganglia Anatomy 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 208000002109 Argyria Diseases 0.000 description 1
- 241001203868 Autographa californica Species 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000222128 Candida maltosa Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000896693 Disa Species 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101000941893 Felis catus Leucine-rich repeat and calponin homology domain-containing protein 1 Proteins 0.000 description 1
- 102220538916 Flap endonuclease 1_K80A_mutation Human genes 0.000 description 1
- 101100404646 Gallus gallus NGF gene Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102220533243 Glycophorin-B_Y51A_mutation Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 239000012580 N-2 Supplement Substances 0.000 description 1
- 108091008604 NGF receptors Proteins 0.000 description 1
- 101150117329 NTRK3 gene Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 241000337661 Parada Species 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102220531896 Protein POF1B_Y79A_mutation Human genes 0.000 description 1
- 102220551516 Protein kinase C eta type_Q83A_mutation Human genes 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102220481377 Regulation of nuclear pre-mRNA domain-containing protein 1A_R114A_mutation Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 235000014962 Streptococcus cremoris Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 102220506777 Vitelline membrane outer layer protein 1 homolog_Y11A_mutation Human genes 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000235015 Yarrowia lipolytica Species 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005868 electrolysis reaction Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 108010072285 growth inhibitory proteins Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000026045 iodination Effects 0.000 description 1
- 238000006192 iodination reaction Methods 0.000 description 1
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 229950003188 isovaleryl diethylamide Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000000933 neural crest Anatomy 0.000 description 1
- 210000001982 neural crest cell Anatomy 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 230000006576 neuronal survival Effects 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000584 nodose ganglion Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 230000005868 ontogenesis Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 125000000405 phenylalanyl group Chemical group 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 210000002804 pyramidal tract Anatomy 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 102200079946 rs193302889 Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000012868 site-directed mutagenesis technique Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 238000013060 ultrafiltration and diafiltration Methods 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/48—Nerve growth factor [NGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25393794A | 1994-06-03 | 1994-06-03 | |
| PCT/US1995/006918 WO1995033829A1 (en) | 1994-06-03 | 1995-06-01 | Pantropic neurotrophic factors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO965123D0 NO965123D0 (no) | 1996-12-02 |
| NO965123L NO965123L (no) | 1997-02-03 |
| NO317938B1 true NO317938B1 (no) | 2005-01-10 |
Family
ID=22962278
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19965123A NO317938B1 (no) | 1994-06-03 | 1996-12-02 | Pantropisk neurotrofinpolypeptid, fremgangsmate for fremstilling av dette, isolert nukleinsyre, ekspresjonsvektor, vertscelle samt farmasoytisk preparat |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US5728803A (es) |
| EP (1) | EP0763107B1 (es) |
| JP (1) | JPH10501138A (es) |
| CN (1) | CN1159439C (es) |
| AT (1) | ATE280825T1 (es) |
| AU (1) | AU695144B2 (es) |
| BR (1) | BR9508019B1 (es) |
| CA (1) | CA2191064C (es) |
| DE (1) | DE69533698T2 (es) |
| ES (1) | ES2231786T3 (es) |
| FI (1) | FI120237B (es) |
| IL (1) | IL113983A0 (es) |
| MX (1) | MX9605971A (es) |
| NO (1) | NO317938B1 (es) |
| NZ (1) | NZ287762A (es) |
| PT (1) | PT763107E (es) |
| WO (1) | WO1995033829A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728803A (en) * | 1994-06-03 | 1998-03-17 | Genentech, Inc. | Pantropic neurotrophic factors |
| DE19637718A1 (de) * | 1996-04-01 | 1997-10-02 | Boehringer Mannheim Gmbh | Rekombinante inaktive Core-Streptavidin Mutanten |
| HU222666B1 (hu) | 1996-11-15 | 2003-09-29 | Genentech, Inc. | Eljárás neuorotrofinok tisztítására |
| US6391571B1 (en) | 1997-04-01 | 2002-05-21 | Roche Diagnostics Gmbh | Recombinant inactive avidin mutants |
| US6365373B2 (en) | 1997-04-25 | 2002-04-02 | Genentech, Inc. | Nucleic acids encoding NGF variants |
| IL132251A0 (en) * | 1997-04-25 | 2001-03-19 | Genentech Inc | Ngf variants |
| US7452863B1 (en) | 1997-04-29 | 2008-11-18 | Genentech, Inc. | NGF variants |
| US6113947A (en) * | 1997-06-13 | 2000-09-05 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
| US6663899B2 (en) | 1997-06-13 | 2003-12-16 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
| US6652864B1 (en) * | 1998-12-21 | 2003-11-25 | Asilomar Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
| US20040120891A1 (en) * | 1998-12-21 | 2004-06-24 | Craig Hill | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
| GB0024550D0 (es) | 2000-10-06 | 2000-11-22 | Oxford Biomedica Ltd | |
| CN101653604A (zh) * | 2001-05-30 | 2010-02-24 | 基因技术股份有限公司 | 抗ngf抗体用于治疗各种疾病 |
| AU2003259846A1 (en) * | 2002-08-16 | 2004-03-03 | The General Hospital Corporation | Non-invasive functional imaging of peripheral nervous system activation in humans and animals |
| US8066997B2 (en) * | 2002-12-20 | 2011-11-29 | Anders Nykjaer | Modulation of activity of neurotrophins |
| US20080260722A1 (en) * | 2004-12-30 | 2008-10-23 | The Johns Hopkins University Johns Hopkins Technology Transfer | Method for High Efficiency Survival/Proliferation of Human Embyonic Stem Cells and Human Embryo Survival in Culture |
| RS60019B1 (sr) * | 2006-12-21 | 2020-04-30 | H Lundbeck As | Modulacija aktivnosti proneurotrofina |
| WO2009062149A1 (en) * | 2007-11-08 | 2009-05-14 | Creighton University | Methods for maintaining inner ear neurons |
| US8447409B2 (en) * | 2008-10-15 | 2013-05-21 | Cochlear Limited | Electroneural interface for a medical implant |
| US8259461B2 (en) * | 2008-11-25 | 2012-09-04 | Micron Technology, Inc. | Apparatus for bypassing faulty connections |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9783602B2 (en) | 2010-12-01 | 2017-10-10 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| EP4292649A3 (en) * | 2016-03-18 | 2024-02-21 | Staidson(Beijing) Biopharmaceuticals Co., Ltd. | Fusion protein comprising nerve growth factor and preparation method and use thereof |
| CN112409471B (zh) * | 2016-04-13 | 2022-07-29 | 舒泰神（北京）生物制药股份有限公司 | 低痛神经生长因子突变体 |
| CN110183536B (zh) * | 2018-02-22 | 2021-01-15 | 中国科学院遗传与发育生物学研究所 | 一种复合支架材料及其应用 |
| MX2021000644A (es) | 2018-07-18 | 2021-08-19 | Manzanita Pharmaceuticals Inc | Conjugados para suministrar un agente contra el cancer a las celulas nerviosas, metodos de uso y metodos para la elaboracion de los mismos. |
| CN110812532A (zh) * | 2019-08-20 | 2020-02-21 | 中山大学 | 一种靶向促进皮质脊髓束连接以修复脊髓损伤的组织工程支架的构建方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5169764A (en) * | 1990-08-08 | 1992-12-08 | Regeneron Pharmaceuticals, Inc. | Multitrophic and multifunctional chimeric neurotrophic factors, and nucleic acids and plasmids encoding the chimeras |
| US5488099A (en) * | 1992-03-06 | 1996-01-30 | Persson, Deceased; Hakan B. | Multifunctional chimeric neurotrophic factors |
| US5349055A (en) * | 1992-03-06 | 1994-09-20 | Persson Hakan B | Nerve growth factor having altered receptor binding specificities |
| EP0644937A4 (en) * | 1992-06-12 | 1995-05-03 | Regeneron Pharmaceuticals, Inc. | Therapeutic and diagnostic methods based on neurotrophin-4 expression. |
| US5753225A (en) | 1993-12-03 | 1998-05-19 | The Regents Of The University Of California | Antibodies that mimic actions of neurotrophins |
| AU1282895A (en) * | 1993-12-29 | 1995-07-17 | Sumitomo Pharmaceuticals Company, Limited | Novel human ciliary neurotrophic factor |
| US5728803A (en) * | 1994-06-03 | 1998-03-17 | Genentech, Inc. | Pantropic neurotrophic factors |
| US7144983B1 (en) * | 1997-02-03 | 2006-12-05 | Genentech, Inc. | Pantropic neurotrophic factors |
-
1995
- 1995-05-12 US US08/440,049 patent/US5728803A/en not_active Expired - Lifetime
- 1995-05-15 US US08/441,513 patent/US5981480A/en not_active Expired - Lifetime
- 1995-06-01 WO PCT/US1995/006918 patent/WO1995033829A1/en active IP Right Grant
- 1995-06-01 CA CA002191064A patent/CA2191064C/en not_active Expired - Lifetime
- 1995-06-01 AT AT95921550T patent/ATE280825T1/de active
- 1995-06-01 JP JP8501183A patent/JPH10501138A/ja active Pending
- 1995-06-01 CN CNB951933817A patent/CN1159439C/zh not_active Expired - Lifetime
- 1995-06-01 BR BRPI9508019-8A patent/BR9508019B1/pt not_active IP Right Cessation
- 1995-06-01 EP EP95921550A patent/EP0763107B1/en not_active Expired - Lifetime
- 1995-06-01 PT PT95921550T patent/PT763107E/pt unknown
- 1995-06-01 IL IL11398395A patent/IL113983A0/xx not_active IP Right Cessation
- 1995-06-01 NZ NZ287762A patent/NZ287762A/xx not_active IP Right Cessation
- 1995-06-01 AU AU26592/95A patent/AU695144B2/en not_active Expired
- 1995-06-01 ES ES95921550T patent/ES2231786T3/es not_active Expired - Lifetime
- 1995-06-01 MX MX9605971A patent/MX9605971A/es active IP Right Grant
- 1995-06-01 DE DE69533698T patent/DE69533698T2/de not_active Expired - Lifetime
-
1996
- 1996-12-02 NO NO19965123A patent/NO317938B1/no not_active IP Right Cessation
- 1996-12-03 FI FI964833A patent/FI120237B/fi not_active IP Right Cessation
-
1997
- 1997-02-03 US US08/794,028 patent/US6503728B1/en not_active Expired - Fee Related
- 1997-04-25 US US08/845,541 patent/US6333310B1/en not_active Expired - Lifetime
-
2006
- 2006-05-30 US US11/443,576 patent/US7528233B2/en not_active Expired - Fee Related
-
2009
- 2009-03-10 US US12/401,483 patent/US7935671B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| BR9508019B1 (pt) | 2012-06-12 |
| ATE280825T1 (de) | 2004-11-15 |
| FI964833A0 (fi) | 1996-12-03 |
| WO1995033829A1 (en) | 1995-12-14 |
| FI964833A (fi) | 1996-12-03 |
| FI120237B (fi) | 2009-08-14 |
| US7528233B2 (en) | 2009-05-05 |
| US5981480A (en) | 1999-11-09 |
| ES2231786T3 (es) | 2005-05-16 |
| US5728803A (en) | 1998-03-17 |
| EP0763107B1 (en) | 2004-10-27 |
| AU2659295A (en) | 1996-01-04 |
| US7935671B2 (en) | 2011-05-03 |
| PT763107E (pt) | 2005-02-28 |
| US6333310B1 (en) | 2001-12-25 |
| BR9508019A (pt) | 1997-09-09 |
| MX9605971A (es) | 1997-12-31 |
| CN1159439C (zh) | 2004-07-28 |
| US20060270838A1 (en) | 2006-11-30 |
| CA2191064C (en) | 2009-11-03 |
| CA2191064A1 (en) | 1995-12-14 |
| NZ287762A (en) | 1999-01-28 |
| NO965123L (no) | 1997-02-03 |
| CN1153528A (zh) | 1997-07-02 |
| US20100184656A1 (en) | 2010-07-22 |
| AU695144B2 (en) | 1998-08-06 |
| EP0763107A1 (en) | 1997-03-19 |
| DE69533698T2 (de) | 2006-02-09 |
| US6503728B1 (en) | 2003-01-07 |
| DE69533698D1 (de) | 2004-12-02 |
| IL113983A0 (en) | 1995-10-31 |
| NO965123D0 (no) | 1996-12-02 |
| JPH10501138A (ja) | 1998-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO317938B1 (no) | Pantropisk neurotrofinpolypeptid, fremgangsmate for fremstilling av dette, isolert nukleinsyre, ekspresjonsvektor, vertscelle samt farmasoytisk preparat | |
| US6365373B2 (en) | Nucleic acids encoding NGF variants | |
| Urfer et al. | The binding epitopes of neurotrophin‐3 to its receptors trkC and gp75 and the design of a multifunctional human neurotrophin. | |
| Lu | BDNF and activity-dependent synaptic modulation | |
| US8101571B2 (en) | Treatment methods using NGF variants | |
| Lindsay | Role of neurotrophins and trk receptors in the development and maintenance of sensory neurons: an overview | |
| Fryer et al. | Truncated trkB Receptors on Nonneuronal Cells Inhibit BDNF-Induced Neurite Outgrowthin Vitro | |
| US6472178B1 (en) | Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof | |
| Ohira et al. | A new aspect of the TrkB signaling pathway in neural plasticity | |
| Zhou et al. | Localization of neurotrophin-3-like immunoreactivity in peripheral tissues of the rat | |
| US7144983B1 (en) | Pantropic neurotrophic factors | |
| AU2002300365B9 (en) | NGF Variants | |
| WO2001047946A9 (en) | GFRα1-RET SPECIFIC AGONISTS AND METHODS THEREFOR | |
| Tonra | Classical and novel directions in neurotrophin transport and research: Anterograde transport of brain‐derived neurotrophic factor by sensory neurons | |
| Ross et al. | Axonal transport of the trkA high-affinity NGF receptor | |
| Cuello | Neurotrophins and neurodegenerative diseases | |
| WJ et al. | Neurotrophin Actions in the Brain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |